Controversy Over Proposed Tobacco Tax Reduction in Georgia

Regulations by 2FIRSTS.ai
Mar.11.2024
Controversy Over Proposed Tobacco Tax Reduction in Georgia
Kaha Gvinianidze, the coordinator of the non-communicable diseases program at the World Health Organization, expressed shock at Georgia's proposal to reduce the tobacco consumption tax from 60 Georgian lari (22.60 US dollars) to 30 Georgian lari (11.30 US dollars). WHO official expresses disbelief over Georgia's plan to reduce tobacco tax, contradicting national policy.

According to a report by Sputnik on March 10th, Kaha Gvinianidze, the coordinator of the non-communicable diseases program at the World Health Organization, expressed shock at Georgia's proposal to reduce the tobacco consumption tax from 60 Georgian lari (22.60 US dollars) to 30 Georgian lari (11.30 US dollars). Gvinianidze stated that this measure goes against the government's tobacco control policy implemented in 2021.

 

This violates the national tobacco control policy approved in 2021, the Framework Convention on Tobacco Control to which Georgia is a signatory, as well as Directive 283 of the association.

 

According to the initiative of David Songulashvili, Chair of the Parliamentary Economic Policy Committee, and other members, a bill has been registered in parliament aimed at reducing the tax rate on tobacco products from 60 Georgian Lari ($22.60) to 30 Georgian Lari ($11.30). Documents published on the parliament's website show that if the legislative initiative is passed, budget tax revenues will decrease.

 

However, the proposal has received support from the majority party members in Parliament, who claim that this will help stimulate industry development, increase market competitiveness, and reduce the importation of illegal tobacco.

 

Georgia and the European Union signed an agreement that includes a provision to increase tobacco taxes, with a commitment to fully implement it by 2022. However, this agreement has been extended until 2026.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former FDA Scientist Questions ZYN Review Over Pouch Material and Microplastic Risk
Former FDA Scientist Questions ZYN Review Over Pouch Material and Microplastic Risk
A former FDA toxicologist has questioned whether the agency fully assessed the material used in ZYN nicotine pouches before authorizing them for sale, raising concerns over possible microplastic exposure, according to STAT and The Examination.
Jul.16
France Vape Market 2026: Use Reaches 7.9% Amid Tax, Regulatory and Scientific Debate
France Vape Market 2026: Use Reaches 7.9% Amid Tax, Regulatory and Scientific Debate
France remains one of Europe’s active vape markets in 2026, with adult vaping prevalence rising to 7.9%; at the same time, e-liquid taxation, public-space restrictions, advertising compliance and health-risk debate are pushing the industry into a critical policy period.
Jun.23
UK Vaping Products Duty to Raise £565 Million by 2030/31
UK Vaping Products Duty to Raise £565 Million by 2030/31
The UK will introduce Vaping Products Duty on all vaping liquids from October 1, 2026, with government revenue forecast to rise from £135 million in 2026/27 to £565 million by 2030/31.
Jun.18
Italian Court Ends Six-Year Cigarette Excise Dispute, Rejecting Damages Claim
Italian Court Ends Six-Year Cigarette Excise Dispute, Rejecting Damages Claim
Italy’s Lazio Regional Administrative Court has dismissed an appeal by Italian Tobacco Manufacturing and Manifattura Italiana Tabacco over the cigarette excise calculation mechanism, upholding the minimum tax burden rules and excluding compensation for smaller tobacco operators.
News
Jun.26 by 2Firsts Perspectives
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
British American Tobacco (BAT) subsidiary Vuse Alto has recently adjusted its price tiers in U.S. convenience store channels, leveraging low-cost device kits and pod promotions to reinforce its positioning in the mid-priced closed-system e-cigarette market.
Jun.17
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02